Navigation Links
New Drug Approved for Treatment of Non Small Cell Lung Cancer in Specific Patient Population

WASHINGTON, Sept. 1, 2011 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive.  The drug was approved based on data from two clinical trials, both of which showed a significant increase in overall survival.  

Xalkori targets the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) mutation. According to the FDA, the mutation is only present in 1-7% of people with NSCLC, primarily those diagnosed with adenocarcinoma.

"This is exciting news," said LCA President & CEO, Laurie Fenton Ambrose.  "Personalized medicine is where we are headed for lung cancer treatments.  This is one of the first steps towards identifying medications that help select populations of people.  We must continue to identify other mutations and find drugs that treat them to finally see cures for lung cancer." 

"I was enrolled in the phase I trial for this drug," said Linnea Duff, NH resident and longtime lung cancer survivor.  "At the time I began the trial, I was hoping to have my life extended for a few months. Instead, I got three more years to spend with my family and friends. In addition, because this was a targeted therapy, the side effects were minimal and my quality of life during this time has been remarkable."

Xalkori has shown a life changing response to lung cancer in those patients who are ALK positive.  Lung Cancer Alliance encourages lung cancer patients to discuss genetic testing options with their health care team.  

It is important to note that many genetic mutations have been identified but not all have drugs to target the mutations at this time. With continued focus from researchers and increased participation in clinical trials, more and more of these personalized therapies will become available.  

For more information about clinical trials, please call the Lung Cancer Clinical Trial Matching Service, 800-698-0931.

Lung Cancer Alliance is the only national non-profit organization dedicated exclusively to patient support and advocacy for those living with or at risk for lung cancer.  Lung Cancer Alliance is committed to leading the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.

Follow Lung Cancer Alliance on Facebook:  

Media Contact:
Kay Cofrancesco

SOURCE Lung Cancer Alliance
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unapproved Emergency Birth Control Medicine Possibly in U.S. Distribution May Be Ineffective and Unsafe
2. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
3. Shire plc: Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
4. Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis
5. TandemHeart Approved for Expanded Reimbursement
6. Breast Cancer Patients and Families Decry FDA Panel Vote to Remove Life Saving Drug From Approved List
7. Laureates Electronic Submission Gateway Approved
8. Capacity Constraints Continue to Loosen for Suzhou Erye Pharmaceuticals as a New Production Line is Approved by the China SFDA
9. Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatisms Congress
10. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
11. FDA Expands Approved Use For Carotid Stent
Post Your Comments:
(Date:12/1/2015)... Assurex Health, Inc. today announced a ... providers an expanded range of options in helping ... depression, anxiety, bipolar disorder, posttraumatic stress disorder (PTSD), ... i .   --> i ... of two new drug classes, 17 FDA-approved medications ...
(Date:12/1/2015)... Virginia , 1 de diciembre de ... en tecnología para cuchillas de precisión, develó ... programa de identidad de marca. El nuevo ... el diseño y la ingeniería de productos ... la diferencia". ...
(Date:12/1/2015)... 1, 2015  AccuTEC Blades, a leader in ... logo and brand identity program. The new logo ... of bladed products where "the edge makes all ... --> Serving manufacturers and distributors of medical, ... equipment, AccuTEC,s product lines include those acquired when ...
Breaking Medicine Technology:
(Date:12/1/2015)... PA (PRWEB) , ... December 01, 2015 , ... ... imaging facilities, radiographic technicians must mark the film for accurate interpretation by the ... track of. Fortunately, an inventor from Sacramento, Calif., has found a way to ...
(Date:12/1/2015)... ... 2015 , ... McLean, VA., December 1, 2015 - Octo ... sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT Services ... engineering, infrastructure, as well as operations and sustainment support to the NGA’s Agile ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , ... membership and leadership since 2008. Gary Bruce, President of PartnerTech North America, currently ... spent a significant amount of time in Sweden since joining PartnerTech based in ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani ... support Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center ...
(Date:11/30/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... honors Christina Colon as a 2015-2016 inductee into its VIP Woman ... in pharmacy. NAPW is the nation’s leading networking organization exclusively for professional women, ...
Breaking Medicine News(10 mins):